Johnson & Jonson
Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis
June 27, 2018Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis
Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …
Tylenol recall warrants thorough, public investigation, says ISMP
November 15, 2010Manufacturing and Production FDA, ISMP, Institute for Safe Medication Practices, Johnson & Jonson, MedWatch, Tylenol, Tylenol recall
Johnson & Jonson’s recall of Tylenol painkiller products was one of the key safety trends identified in the last quarter …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
